Physician profile
Haimavathi Bhat
NPI 1861625741
$663.01
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.29 · 2020: $133 · 2021: $148 · 2022: $43.03 · 2023: $152 · 2024: $94.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $183.49 | 2019-2024 | Rukobia |
| Merck Sharp & Dohme LLC | $107.66 | 2019-2024 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $99.59 | 2021-2022 | |
| Insmed, INC. | $64.08 | 2020-2021 | |
| Theratechnologies INC. | $55.95 | 2023-2024 | Egrifta, Trogarzo |
| Tetraphase Pharmaceuticals, INC. | $44.90 | 2019-2020 | |
| Shionogi INC | $28.86 | 2021 | |
| Paratek Pharmaceuticals, INC. | $21.88 | 2020 | |
| Vyera Pharmaceuticals, LLC | $20.67 | 2019 | |
| Melinta Therapeutics, LLC | $19.91 | 2020 | |
| Janssen Biotech, INC. | $16.02 | 2023 | Symtuza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haimavathi Bhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.